HIV VACCINE AWARENESS DAY
MAY 18th

AfNHi
Africa free of New HIV infections

AfNHi Youth Cohort

26 YEARS LATER

Dear Friends and Partners, Happy HIV Vaccines Awareness Day!

AfNHi extends heartfelt greetings to everyone on this significant day –observed every year on May 18 and commemorates U.S. President Bill Clinton's 1997 declaration that "only a truly effective, preventive HIV vaccine can limit and eventually eliminate the threat of AIDS." It recognizes the many volunteers, community members, health professionals, and scientists working together to develop a vaccine to prevent HIV. It is also an opportunity to educate communities about the importance of preventive HIV vaccine research. A safe and effective preventive HIV vaccine would play an essential role in ensuring the end of the HIV pandemic. This day provides us with an opportunity to reflect on the progress we have made in the fight against HIV and to raise awareness about the importance of vaccines in preventing the transmission and progression of HIV. HIV continues to be one of the most pressing global health challenges, particularly in sub-Saharan Africa, where the burden of the disease remains disproportionately high. Despite the remarkable achievements in expanding access to antiretroviral therapy (ART) and improving the overall management of HIV, we recognize that a vaccine is crucial in our efforts to achieve an HIV-free generation.

While significant strides have been made in HIV vaccine research, we must acknowledge that the journey toward a safe, effective, and accessible vaccine is still ongoing. We commend the scientific community, researchers, and organizations involved in the development and testing of potential vaccines, as their dedication and perseverance are bringing us closer to this important milestone. HIV vaccines are a vital area of research and development in the fight against the HIV pandemic. There are two main types of HIV vaccines being studied: i). Preventive Vaccines: designed to protect individuals who are HIV-negative from acquiring the virus. They typically work by stimulating an immune response that can recognize and neutralize the virus if a person is exposed to it. Several preventive vaccine candidates have been tested in clinical trials with significant progress, however, no vaccine has been approved for use at the moment. ii). therapeutic vaccines, intended to be used in individuals who are already living with HIV. These vaccines aim to stimulate or enhance the immune response to control the virus and slow down disease progression. Therapeutic vaccines can potentially reduce the need for ART or improve the effectiveness of existing treatments. Several therapeutic vaccine candidates have shown promising results in early-phase clinical trials, but further research is needed to determine their long-term effectiveness and safety.

Developing an HIV vaccine poses unique challenges due to the complex nature of the virus and its ability to mutate and evade the immune system. Scientists and researchers worldwide are collaborating to overcome these challenges, and ongoing clinical trials are crucial to evaluate the safety and efficacy of potential vaccine candidates. It's important to note that while the development of an HIV vaccine is a high priority, it takes time to ensure the safety and effectiveness of any vaccine before it can be approved for widespread use. In the meantime, other prevention methods, such as practicing safe sex, using condoms and pre-exposure prophylaxis (PrEP), undergoing regular HIV testing, and adhering to antiretroviral treatment, remain vital in reducing the transmission and impact of HIV. In addition to the development of an HIV vaccine, we must also address the social, economic, and cultural factors that contribute to the spread of HIV. This includes promoting comprehensive sex education, ensuring access to affordable and high-quality healthcare services, and combating stigma and discrimination towards people living with HIV as well as upholding the highest standards of human rights and respect for the most vulnerable populations among us, without any form of discrimination that may lead communities not to access HIV prevention and treatment services.

As we commemorate this day, let us reaffirm our commitment to ending the HIV pandemic. Together, we can accelerate progress toward finding an effective vaccine and ensure that it is accessible to all who need it, regardless of their geographic location or socioeconomic status. Let us unite in our efforts to raise awareness, educate communities, and advocate for the prioritization of HIV vaccine research. By working hand in hand, we can create a future where HIV is no longer a threat to the health and well-being of individuals and communities across Africa and the world.

Today, we call upon governments, decision-makers, donors, policymakers, and stakeholders across the African continent and beyond to prioritize and invest in HIV vaccine research and development. It is imperative that adequate resources are allocated to support ongoing clinical trials and vaccine manufacturing, African scientists are supported and provided with an enabling infrastructure and funding to foster local expertise ensuring that solutions are tailored to meet the local needs and to suit the African context in addition to strengthening the health systems to ensure the effective distribution and delivery of future vaccines.

Africa Free of New HIV Infections

18TH MAY 2023